Exploration of surface glycoprotein to design multi-epitope vaccine for the prevention of Covid-19

dc.contributor.authorOladipo, Elijah Kolawole
dc.contributor.authorAjayi, Ayodeji Folorunsho
dc.contributor.authorAriyo, Olumuyiwa Elijah
dc.contributor.authorOnile, Samson Olugbenga
dc.date.accessioned2021-05-27T15:15:36Z
dc.date.available2021-05-27T15:15:36Z
dc.date.issued2020-09-27
dc.descriptionStaff Publicationen_US
dc.description.abstractStimulation and generation of T and B cell-mediated long-term immune response are essential for the curbing of a deadly virus such as SAR-CoV-2 (Severe Acute Respiratory Corona Virus 2). Immunoinformatics approach in vaccine design takes advantage of antigenic and non-allergenic epitopes present on the spike glycoprotein of SARS-CoV-2 to elicit immune responses. T cells and B cells epitopes were predicted, and the selected residues were subjected to allergenicity, antigenicity and toxicity screening which were linked by appropriate linkers to form a multi-epitope subunit vaccine. The physiochemical properties of the vaccine construct were analyzed, and the molecular weight, molecular formula, theoretical isoelectric point value, half-life, solubility score, instability index, aliphatic index and GRAVY were predicted. The vaccine structure was constructed, refined, validated, and disulfide engineered to get the best model. Molecular binding simulation and molecular dynamics simulation were carried out to predict the stability and binding affinity of the vaccine construct with TLRs. Codon acclimatization and in silico cloning were performed to confirm the vaccine expression and potency. Results obtained indicated that this novel vaccine candidate is non-toxic, capable of initiating the immunogenic response and will not induce an allergic reaction. The highest binding energy was observed in TLR4 (Toll-like Receptor 4) (􀀀 1398.1), and the least is TLR 2 (􀀀 1479.6). The steady rise in Th (T-helper) cell population with memory development was noticed, and IFN-g (Interferon gamma) was provoked after simulation. At this point, the vaccine candidate awaits animal trial to validate its efficacy and safety for use in the prevention of the novel COVID-19 (Coronavirus Disease 2019) infections.en_US
dc.identifier.urihttps://doi.org/10.1016/j.imu.2020.100438
dc.identifier.urihttp://repository.elizadeuniversity.edu.ng/handle/20.500.12398/1025
dc.language.isoenen_US
dc.publisherInformatics in Medicine Unlockeden_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectSubunit vaccineen_US
dc.subjectTLRsen_US
dc.subjectImmunityen_US
dc.titleExploration of surface glycoprotein to design multi-epitope vaccine for the prevention of Covid-19en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1-s2.0-S2352914820305888-main.pdf
Size:
13.68 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.61 KB
Format:
Item-specific license agreed upon to submission
Description: